Revvity (NYSE:RVTY - Get Free Report) had its price objective upped by JPMorgan Chase & Co. from $160.00 to $165.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 10.37% from the company's current price.
Several other brokerages have also issued reports on RVTY. Cfra raised Revvity from a "hold" rating to a "buy" rating in a research report on Wednesday, November 4th. UBS Group initiated coverage on Revvity in a research report on Wednesday, September 9th. They set a "neutral" rating and a $140.00 price target on the stock. Zacks Research raised shares of Revvity from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Sanford C. Bernstein reissued a "market perform" rating on shares of Revvity in a research note on Thursday. Finally, Weiss Ratings raised shares of Revvity from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat, Revvity presently has a consensus rating of "Hold" and an average target price of $134.21.
Get Our Latest Report on Revvity
Revvity Trading Down 3.2%
Shares of RVTY stock traded down $4.89 during mid-day trading on Monday, reaching $149.50. The stock had a trading volume of 564,370 shares, compared to its average volume of 1,537,487. Revvity has a 52-week low of $81.22 and a 52-week high of $171.74. The firm has a market capitalization of $16.69 billion, a PE ratio of 66.31, a price-to-earnings-growth ratio of 2.70 and a beta of 1.08. The company has a current ratio of 2.65, a quick ratio of 2.10 and a debt-to-equity ratio of 0.36. The stock's 50-day moving average price is $150.48 and its two-hundred day moving average price is $114.30.
Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, beating analysts' consensus estimates of $1.30 by $0.08. The business had revenue of $728.90 million during the quarter, compared to analyst estimates of $694.73 million. Revvity had a return on equity of 8.64% and a net margin of 8.61%. Revvity's quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 EPS. Equities analysts expect that Revvity will post 5.42 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Tajinder S. Vohra sold 7,330 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider owned 6,635 shares of the company's stock, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the business's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider owned 14,781 shares of the company's stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,045 shares of company stock valued at $1,281,439 in the last ninety days. Insiders own 0.85% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. Apollon Wealth Management LLC boosted its stake in shares of Revvity by 2.7% during the third quarter. Apollon Wealth Management LLC now owns 2,778 shares of the company's stock valued at $425,000 after purchasing an additional 73 shares in the last quarter. Moors & Cabot Inc. increased its holdings in Revvity by 3.1% during the third quarter. Moors & Cabot Inc. now owns 2,448 shares of the company's stock valued at $374,000 after buying an additional 73 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Revvity by 5.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company's stock worth $231,000 after buying an additional 106 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Revvity by 17.0% in the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company's stock worth $66,000 after buying an additional 109 shares in the last quarter. Finally, Angeles Wealth Management LLC raised its stake in Revvity by 2.0% in the second quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company's stock worth $646,000 after buying an additional 112 shares in the last quarter. 86.65% of the stock is currently owned by institutional investors.
About Revvity
(
Get Free Report)
Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company's work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.